Board of Directors

Seng Chin Mah is an independent healthcare advisor with over 30 years’ experience in the Pharma and Biotech industry. Dr. Mah was formerly the Chief Executive Officer of the Canyon Pharmaceuticals Group AG. Prior to Canyon, he was the Head of Development of the Integration Office during the integration of Chiron into Novartis and has previously held positions including Global Head of Clinical Safety and Epidemiology, Head of Drug Regulatory Affairs Europe. He also had oversight responsibility for Clinical Quality Assurance. Dr. Mah was also a member of the Novartis Corporate Executive Group and a member of the board of directors for Novartis Europharm Ltd. During his tenure with Novartis and Ciba, he has driven transformational programs, managed large global organizations, and achieved significant business results such as the numerous global registrations of major products including Diovan. Dr. Mah has worked extensively on both development projects and marketed products. He has held numerous research and academia positions, and is currently on the boards of several biotech companies. Dr. Mah is an award-winning CEO of a biotech - The Frost & Sullivan 2011 Product Differentiation Excellence Award in Parenteral Anticoagulants recognized Canyon Pharmaceuticals Group AG for the development and launch of Iprivask® (desirudin for injection). He subsequently effected an asset transaction of the product. He possesses deep knowledge in strategic decision-making within the Pharma and Biotech industry, late stage clinical development & regulatory experience as well as people development skills.

Marc is Chief Executive Officer and co-founder of BioVersys with over 10 years of experience in the biotech industry, having launched a university spin-off in the field of antimicrobial resistance and growing it into a multi-asset clinical stage company. Some of these assets will address significant unmet medical needs in infectious conditions such as tuberculosis and hospital acquired Acinetobacter infections. Marc has raised over $70 mio in equity financing and secured over $30 mio in non-dilutive funding. He has also established several important partnerships with a Big Pharma and other development organizations. Multi-award-winning Biotech CEO, having received amongst others the Swiss Technology Award 2011, Venture Kick 2009 and Venture Leaders 2008 and 2017 awards for his work in founding and advancing BioVersys. He is also President of the Board of the BEAM Alliance, a European association representing over 70 European and international SMEs active in antimicrobial research and development and Board member of AMR Industry Alliance. Marc is a young thought leader in the field of antimicrobial research and development. He is passionate about next generation antimicrobial therapies and leads a highly motivated team striving to bring life-saving antimicrobial therapies to patients in need. He is also co-author on several high ranked scientific publications and patents in the field.

Marina von Schönau is Chairwoman of Almacos AG and investor representative of a family office where she takes care of the private equity portfolio. Almacos AG is a management consultancy that is active in companies in the private equity space in real estate, healthcare including digital health, recycling, food appliances and financial services, with an emphasis on helping management retain entrepreneurial values. She holds various board positions in privately held companies, including dacadoo AG as well as foundations such as the Coralma Stiftung AG. Over the last decade, Ms. von Schönau has been focused on advising venture opportunities, growth scenarios and complex restructurings especially within biotechnology, digital healthcare and recycling. As an investor, she has particular interests in the healthcare sector especially nutrition and in the recycling industry. In her prior career, Ms. von Schönau has worked in senior positions at different multi-national companies in the pharmaceutical sector including Janssen Cilag AG and Bayer (Schweiz) AG where she gained in depth knowledge of marketing, product launches and leadership. She has worked on products in the central nervous system (CNS) therapeutic area and women’s health. She was also a member of an international marketing frame group for a new product where she drove e-business ideas. Under her leadership, the CNS therapeutic area played a leading role in the initiation and expansion of the company's e-business platforms. Ms. von Schönau has a strong interest in the tremendous business potential and culture of Asia, in particular the fast pace of innovation in the fields of nutrition and hedge fund portfolios.

William Jenkins is an independent healthcare advisor with over 40 years’ experience and is principal of William Jenkins Pharma Consulting where he has been advising a wide range of pharma and biotech companies as well as investment and venture capital firms in the healthcare sector. Dr. Jenkins has previously served on the boards of multiple Biotechs including Consort Medical Ltd, Allecra Therapeutics, Ablynx N.V., BTG PLC, Eurand Pharmaceutical Holdings B.V., Vaxxim AG, Monogram Biosciences Inc, Acambis Research Ltd, Evotec AG, Tanox Inc, Nicholas Piramal India Ltd and Glycart AG. He has been involved in corporate transactions ranging from mergers & acquisitions, demergers and IPOs to licensing deals across several geographies. He has also been a member of several Scientific Advisory Boards of biotechs and venture capital funds. Formerly, Dr. Jenkins has held positions such as the Global Head of Clinical Development & Regulatory Affairs of Novartis, Head of Medicine of Ciba and Head of Worldwide Clinical Research of the Glaxo Group where he was responsible for the successful development and approval of numerous novel products across all therapeutic areas and contributed to their successful launches. Before joining the pharmaceutical industry, Dr. Jenkins was Principal Medical Officer and a Deputy Head of the Medicines Division of the UK Department of Health where he was also the UK representative to the CPMP on Adverse Drug Reactions. He has also been a Senior Lecturer in Medicine and a Medical Research Council Fellow.

Shlomo Noy is a partner and Chief Medical Officer (CMO) of the Guangzhou Israel Biotech Fund (GIBF) with over 30 years of professional experience in the life sciences industry, covering a wide range of disciplines. Dr. Noy played a key role in managing the first fund which closed in 2022 with 12 portfolio companies and a total of $100 million under management. Since 2022, GIBF fund 2 has expanded to $300 million under management focusing on pharma therapeutics and has completed four investments to date. Prior to that, Dr. Noy served as the Vice-President for Research & Development at Sheba Medical Center, the largest hospital in Israel, which has been ranked among the top 10 hospitals in the world by Businessweek. He was the founder and chairman of the Sheba Tech Transfer Company, which achieved exits totalling over NIS 550 million. He has also held the position of Chairman of the Helsinki Committee for Human Trials (IRB), overseeing more than 3,000 human trials annually. Dr. Noy has acted as a consultant to the National Healthcare Reform Committee and served as a life sciences consultant for PWC. He is a Board member of Sheba Medical Center’s life sciences company, and various biotech companies.